Chapter V.2. Treatment of Alzheimer's Disease (With or Without Cerebrovascular Disease)

  1. Nawab Qizilbash MBChB, MRCP, MSc, DPhil (Oxon)1,2
  1. Lon S. Schneider,
  2. Nawab Qizilbash,
  3. Mary Sano,
  4. Fadi Massoud,
  5. Jeffrey Kaye,
  6. Jason T. Olin,
  7. Knut Laake,
  8. Anne Rita Øksengaard,
  9. Barry S. Oken,
  10. Kristine Yaffe,
  11. Kentaro Hashimoto,
  12. Jesus López-Arrieta,
  13. John C. S. Breitner,
  14. Leon Flicker,
  15. Kenneth Rockwood and
  16. Josẽ Luísrodríquez-Martin

Published Online: 14 JAN 2008

DOI: 10.1002/9780470752340.ch34

Evidence-based Dementia Practice

Evidence-based Dementia Practice

How to Cite

Schneider, L. S., Qizilbash, N., Sano, M., Massoud, F., Kaye, J., Olin, J. T., Laake, K., Rita Øksengaard, A., Oken, B. S., Yaffe, K., Hashimoto, K., López-Arrieta, J., Breitner, J. C. S., Flicker, L., Rockwood, K. and Luísrodríquez-Martin, J. (2003) Treatment of Alzheimer's Disease (With or Without Cerebrovascular Disease), in Evidence-based Dementia Practice (ed N. Qizilbash), Blackwell Science Ltd, Oxford, UK. doi: 10.1002/9780470752340.ch34

Editor Information

  1. 1

    Visiting Professor of Geriatric Medicine, Hospital Universitario GM-Cantoblanco, 280049 Madrid, Spain

  2. 2

    Member of Green College, Oxford University, Oxford, UK

Publication History

  1. Published Online: 14 JAN 2008
  2. Published Print: 1 JAN 2003

ISBN Information

Print ISBN: 9780632052967

Online ISBN: 9780470752340

SEARCH

Keywords:

  • publications;
  • global impression;
  • memory tests;
  • verbal fluency;
  • pharmacology

Summary

This chapter contains section titled:

  • Introduction

  • Rationale

  • Evidence

  • Drug interactions

  • Dose

  • Future research

  • Summary

  • Number needed to treat

  • Who should be considered for treatment?

  • Clinical pharmacology

  • Adverse effects

  • Evidence

  • Vitamin E and selegiline for AD

  • Rationale

  • Who should be considered for treatment?

  • Clinical pharmacokinetics

  • Adverse events

  • Future research

  • Summary

  • Introduction

  • Evidence

  • Rationale

  • Who should be excluded from treatment?

  • Who should be considered for treatment?

  • Clinical pharmacokinetics

  • Adverse effects

  • Starting/monitoring/stopping treatment

  • Future research

  • Summary

  • Introduction

  • Rationale

  • Evidence

  • Who should be considered for treatment?

  • Clinical pharmacokinetics

  • Adverse effects

  • Who should be excluded from treatment?

  • Starting/monitoring/stopping treatment

  • Future research

  • Summary

  • Introduction

  • Rationale

  • Evidence

  • Who should be considered for treatment?

  • Who should be excluded from treatment?

  • Clinical pharmacokinetics

  • Starting/monitoring/stopping treatment

  • Number needed to treat

  • Isomeric forms of AChE

  • Future research

  • Summary

  • Potential for metrifonate to influence beta-amyloid processing

  • Introduction

  • Rationale

  • Evidence

  • Who should be considered for treatment?

  • Who should be excluded from treatment?

  • Clinical pharmacokinetics

  • Starting/monitoring/stopping treatment

  • Adverse events

  • Future research

  • Summary

  • Summary of number needed to treat

  • Evidence

  • Rationale

  • Who should be considered for treatment?

  • Who should be excluded from treatment?

  • Starting/monitoring/stopping treatment

  • Clinical pharmacokinetics

  • Adverse effects

  • Future research

  • Summary

  • Introduction

  • Animal studies of the role of glutamatergic neurotransmission in memory

  • Pharmacological studies in man

  • Randomized clinical trials of

  • cycloserine in AD

  • Acknowledgement

  • Overview

  • Rationale

  • Evidence

  • Who should be considered for treatment?

  • Who should be excluded from treatment?

  • Clinical pharmacokinetics

  • Adverse effects

  • Future research

  • Starting/monitoring/stopping treatment

  • Summary

  • Introduction

  • Rationale

  • Who should be considered for treatment?

  • Evidence

  • Who should be excluded from treatment?

  • Clinical pharmacokinetics

  • Adverse effects

  • Dosage/monitoring/stopping treatment

  • Summary

  • Numbers needed to treat

  • Future research

  • Introduction

  • Rationale

  • Evidence

  • Who should be considered for treatment?

  • Who should be excluded from treatment?

  • Clinical pharmacokinetics

  • Adverse effects

  • Starting/monitoring/stopping treatment

  • Future research

  • Summary

  • Summary

  • Rationale

  • Evidence

  • Number needed to treat

  • Who should be considered for treatment?

  • Who should be excluded from treatment?

  • Clinical pharmacokinetics

  • Adverse effects

  • Drug interactions

  • Starting/monitoring/stopping treatment

  • Dependency: nursing home placement

  • Number needed to treat

  • Future research

  • Summary

  • Rationale

  • Evidence

  • Who should be considered for treatment?

  • Clinical pharmacokinetics

  • Adverse effects

  • Starting/monitoring/stopping treatment

  • Future research

  • Summary

  • Rationale

  • Clinical global impression

  • Evidence

  • Adverse effects

  • Starting/monitoring/stopping treatment

  • Future research

  • Summary

  • Who should be considered for treatment?

  • Clinical pharmacokinetics

  • Rationale

  • Evidence

  • Starting/monitoring/stopping treatment

  • Future research

  • Summary

  • Who should be considered for treatment?

  • Adverse effects

  • Rationale

  • Evidence

  • Who should be considered for treatment?

  • Adverse effects

  • Future research

  • Rationale

  • Evidence

  • Summary

  • Who should be considered for treatment?

  • Who should be excluded from treatment?

  • Clinical pharmacokinetics

  • Adverse effects

  • Starting/monitoring/stopping treatment

  • Future research

  • Summary

  • Introduction

  • Rationale

  • Evidence

  • Who should be considered for treatment?

  • Who should be excluded from treatment?

  • Clinical pharmacokinetics

  • Adverse effects

  • Summary

  • Starting/monitoring/stopping treatment

  • Future research

  • Rationale

  • Evidence

  • Who should be considered for treatment?

  • Adverse effects

  • Starting/monitoring/stopping treatment

  • Future research

  • Summary

  • Overall summary

  • Aims

  • Methods of this review

  • Practical summary of beneficial or probably beneficial drugs used in practice

  • 1-year trials

  • Treatment considerations

  • Comparison of benefits and harms of approved symptomatic therapies

  • Symptomatic therapy

  • n-

  • Prognosis-modifying therapycfor clinically important endpoints

  • Acknowledgement